Julia H Song1,2, Olga Kantor3,4, Elizabeth A Mittendorf3,4, Tari A King3,4, Christina A Minami5,6,7. 1. Harvard Medical School, Boston, MA, USA. 2. Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA. 3. Division of Breast Surgery, Brigham and Women's Hospital, Boston, MA, USA. 4. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. 5. Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA. cminami@partners.org. 6. Division of Breast Surgery, Brigham and Women's Hospital, Boston, MA, USA. cminami@partners.org. 7. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. cminami@partners.org.
Abstract
BACKGROUND: Women ≥ 65 years of age are less likely to receive guideline-concordant breast cancer care. Given existing racial/ethnic disparities, older minority breast cancer patients may be especially prone to inequalities in care. How site of care impacts older breast cancer patients is not well defined. We sought to evaluate the association between race/ethnicity and breast cancer treatment delays in older women treated at minority-serving hospitals (MSHs) versus non-MSHs. METHODS: Women ≥ 65 years of age treated for non-metastatic breast cancer were identified in the National Cancer Database (2010-2017). Treatment delay was defined as > 90 days from diagnosis to initial treatment. MSHs were defined as the top decile of hospitals serving predominantly Black or Hispanic patients. Multivariable logistic regression models adjusted for patient, tumor, and hospital characteristics were used to determine the odds of treatment delay for women at MSHs versus non-MSHs across racial/ethnic groups. RESULTS: Overall, 557,816 women were identified among 41 MSHs and 1146 non-MSHs. Average time to treatment was 33.71 days (standard deviation 26.92 days). Older women at MSHs were more likely to experience treatment delays than those at non-MSHs (odds ratio 1.28, 95% confidence interval 1.21-1.36). Regardless of where they received care, minorities were more likely to experience treatment delays than non-Hispanic White women. CONCLUSIONS: Although 97% of older women treated at Commission on Cancer-accredited hospitals received timely breast cancer care, minorities and those treated at MSHs were more likely to experience treatment delays. Interventions addressing barriers to timely breast cancer care at MSHs may be an effective approach to reducing racial/ethnic disparities.
BACKGROUND: Women ≥ 65 years of age are less likely to receive guideline-concordant breast cancer care. Given existing racial/ethnic disparities, older minority breast cancer patients may be especially prone to inequalities in care. How site of care impacts older breast cancer patients is not well defined. We sought to evaluate the association between race/ethnicity and breast cancer treatment delays in older women treated at minority-serving hospitals (MSHs) versus non-MSHs. METHODS: Women ≥ 65 years of age treated for non-metastatic breast cancer were identified in the National Cancer Database (2010-2017). Treatment delay was defined as > 90 days from diagnosis to initial treatment. MSHs were defined as the top decile of hospitals serving predominantly Black or Hispanic patients. Multivariable logistic regression models adjusted for patient, tumor, and hospital characteristics were used to determine the odds of treatment delay for women at MSHs versus non-MSHs across racial/ethnic groups. RESULTS: Overall, 557,816 women were identified among 41 MSHs and 1146 non-MSHs. Average time to treatment was 33.71 days (standard deviation 26.92 days). Older women at MSHs were more likely to experience treatment delays than those at non-MSHs (odds ratio 1.28, 95% confidence interval 1.21-1.36). Regardless of where they received care, minorities were more likely to experience treatment delays than non-Hispanic White women. CONCLUSIONS: Although 97% of older women treated at Commission on Cancer-accredited hospitals received timely breast cancer care, minorities and those treated at MSHs were more likely to experience treatment delays. Interventions addressing barriers to timely breast cancer care at MSHs may be an effective approach to reducing racial/ethnic disparities.
Authors: Benjamin D Smith; Jing Jiang; Sandra S McLaughlin; Arti Hurria; Grace L Smith; Sharon H Giordano; Thomas A Buchholz Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Marieke J Krimphove; Sean A Fletcher; Alexander P Cole; Sebastian Berg; Maxine Sun; Stuart R Lipsitz; Brandon A Mahal; Paul L Nguyen; Toni K Choueiri; Adam S Kibel; Luis A Kluth; Joel S Weissman; Quoc-Dien Trinh Journal: J Urol Date: 2019-04 Impact factor: 7.450
Authors: Carol E DeSantis; Jiemin Ma; Mia M Gaudet; Lisa A Newman; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-10-02 Impact factor: 508.702
Authors: Rachel A Freedman; Nancy L Keating; Nancy U Lin; Eric P Winer; Ines Vaz-Luis; Joyce Lii; Pedro Exman; William T Barry Journal: Cancer Date: 2018-03-02 Impact factor: 6.860
Authors: Ahmedin Jemal; Anthony S Robbins; Chun Chieh Lin; W Dana Flanders; Carol E DeSantis; Elizabeth M Ward; Rachel A Freedman Journal: J Clin Oncol Date: 2017-10-16 Impact factor: 44.544
Authors: Clement G Yedjou; Jennifer N Sims; Lucio Miele; Felicite Noubissi; Leroy Lowe; Duber D Fonseca; Richard A Alo; Marinelle Payton; Paul B Tchounwou Journal: Adv Exp Med Biol Date: 2019 Impact factor: 2.622
Authors: Olga Kantor; Monica L Wang; Kimberly Bertrand; Lori Pierce; Rachel A Freedman; Mariana Chavez-MacGregor; Tari A King; Elizabeth A Mittendorf Journal: Ann Surg Oncol Date: 2021-07-30 Impact factor: 5.344
Authors: Alexander P Cole; David-Dan Nguyen; Akezhan Meirkhanov; Mehra Golshan; Nelya Melnitchouk; Stuart R Lipsitz; Kerry L Kilbridge; Adam S Kibel; Zara Cooper; Joel Weissman; Quoc-Dien Trinh Journal: JAMA Netw Open Date: 2019-02-01